Hormonal
GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide) reduce major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and cardiovascular mortality in patients with type 2 diabetes and established cardiovascular disease, as well as in non-diabetic patients with obesity and cardiovascular disease.
If you have Type 2 Diabetes and heart disease, or obesity and heart disease, GLP-1 agonists like semaglutide or liraglutide are proven to significantly lower your risk of heart attack, stroke, and heart-related death. This benefit exists alongside blood sugar control. Discuss with your doctor if you are a candidate, considering the cost and injection/oral delivery options.
GLP-1 agonists achieved substantial reductions in myocardial infarction, stroke, cardiovascular mortality, and heart failure events according to major cardiovascular outcome trials (CVOTs). Recent research, notably the pivotal SELECT trial, has confirmed their suitability for non-diabetic subjects with obesity and established CVD.
Why this rating
Based on multiple large-scale Cardiovascular Outcome Trials (CVOTs) with statistically significant hazard ratios.
Source
GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Han‐Mo Yang · Journal of Clinical Medicine · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →